Five-year quality of life in patients with high-risk localized prostate cancer treated with external beam radiotherapy alone versus external beam radiotherapy with high-dose-rate brachytherapy boost: a prospective multicenter study.
external beam radiotherapy
high-dose-rate brachytherapy
prostate cancer
quality of life
Journal
Journal of contemporary brachytherapy
ISSN: 1689-832X
Titre abrégé: J Contemp Brachytherapy
Pays: Poland
ID NLM: 101506276
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
27
09
2020
accepted:
24
12
2020
entrez:
24
5
2021
pubmed:
25
5
2021
medline:
25
5
2021
Statut:
ppublish
Résumé
Brachytherapy (BT) and external beam radiation therapy (EBRT) are effective treatments for high-risk prostate cancer (PCa). However, the impact of these treatments on health-related quality of life (HRQL) remains unclear. In this study, we compared EBRT alone with EBRT plus a boost with high-dose rate (HDR)-BT to determine the impact on HRQL in patients with high-risk PCa. Prospective, multicenter study comparing patients with high-risk PCa treated with EBRT alone or EBRT + HDR-BT from 2004 to 2006. HRQL was assessed at baseline (pre-treatment) and periodically over the 5-year follow-up, using the SF-36 (v.2), EPIC, and FACT-G and FACT-P questionnaires. A total of 129 patients were included in the study, of these, 41 received EBRT alone and 88 EBRT + HDR-BT. All patients received hormonotherapy. Baseline clinical characteristics were similar, except for a slightly higher mean number of comorbidities in the EBRT group. During follow-up, the only significant between-group difference was a greater worsening on EPIC hormonal domain in the EBRT alone group ( After five years of follow-up, EBRT alone or combined with HDR-BT boost had a similar impact on HRQL in patients with high-risk localized PCa. However, patients in the EBRT alone group experienced greater worsening of hormonal domain according to EPIC questionnaire.
Identifiants
pubmed: 34025730
doi: 10.5114/jcb.2021.103580
pii: 43288
pmc: PMC8117716
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1-11Informations de copyright
Copyright © 2020 Termedia.
Déclaration de conflit d'intérêts
The authors report no conflict of interest.
Références
Int J Radiat Oncol Biol Phys. 2017 Jun 1;98(2):275-285
pubmed: 28262473
Cancer Treat Rev. 2018 Nov;70:265-271
pubmed: 30326422
JAMA. 2012 Apr 18;307(15):1611-20
pubmed: 22511689
N Engl J Med. 2008 Mar 20;358(12):1250-61
pubmed: 18354103
Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):965-74
pubmed: 16798415
Radiother Oncol. 2013 Aug;108(2):306-13
pubmed: 23849168
World J Urol. 2009 Oct;27(5):607-12
pubmed: 19455340
Med Clin (Barc). 1995 May 27;104(20):771-6
pubmed: 7783470
Eur Urol. 1997;31(2):129-40
pubmed: 9076454
JAMA. 2017 Mar 21;317(11):1141-1150
pubmed: 28324092
J Clin Oncol. 2005 Feb 20;23(6):1192-9
pubmed: 15718316
Med Clin (Barc). 2009 Feb 7;132(4):128-35
pubmed: 19211071
Int J Radiat Oncol Biol Phys. 2017 Sep 1;99(1):90-93
pubmed: 28816169
Radiother Oncol. 2014 Aug;112(2):227-32
pubmed: 25174299
J Clin Oncol. 2005 Apr 20;23(12):2772-80
pubmed: 15837992
Lancet. 2002 Jul 13;360(9327):103-6
pubmed: 12126818
Brachytherapy. 2015 Mar-Apr;14(2):166-72
pubmed: 25582682
Clin Perform Qual Health Care. 1993 Oct-Dec;1(4):219-22
pubmed: 10135639
Clin Oncol (R Coll Radiol). 2013 May;25(5):321-7
pubmed: 23384799
Int J Radiat Oncol Biol Phys. 2008 Oct 1;72(2):421-32
pubmed: 18325680
N Engl J Med. 2016 Oct 13;375(15):1425-1437
pubmed: 27626365
N Engl J Med. 2016 Oct 13;375(15):1415-1424
pubmed: 27626136
Med Care. 1998 Sep;36(9):1407-18
pubmed: 9749663
Radiother Oncol. 2002 Jul;64(1):1-12
pubmed: 12208568
Int J Radiat Oncol Biol Phys. 2015 Feb 1;91(2):277-87
pubmed: 25491504
Radiother Oncol. 2012 May;103(2):217-22
pubmed: 22341794
Ann Surg Oncol. 2010 Jun;17(6):1471-4
pubmed: 20180029